Bispecific antibody platforms for cancer immunotherapy

被引：63
|
作者：
Lameris, Roeland [1 ]
de Bruin, Renee C. G. [1 ]
Schneiders, Famke L. [1 ]
Henegouwen, Paul M. P. van Bergen en [2 ]
Verheul, Henk M. W. [1 ]
de Gruijl, Tanja D. [1 ]
van der Vliet, Hans J. [1 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands
[2] Univ Utrecht, Fac Sci, Dept Biol, Div Cell Biol, NL-3584 CH Utrecht, Netherlands
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2014年 / 92卷 / 03期
关键词：
Bi-specific antibodies; Dual specific retargeting; Immune effector cells; Anti-cancer therapy; NATURAL-KILLER-CELLS; DELTA T-CELLS; SINGLE-CHAIN ANTIBODY; EPCAM X ANTI-CD3; ACUTE LYMPHOBLASTIC-LEUKEMIA; EXPRESSING TUMOR-CELLS; NKT CELLS; MALIGNANT ASCITES; ANTITUMOR-ACTIVITY; PROSTATE-CANCER;
D O I：
10.1016/j.critrevonc.2014.08.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Over the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novel bispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinical studies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that were encountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：153 / 165
页数：13
相关论文
共 50 条
  • [1] Review Article Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
    Moon, Dain
    Tae, Nara
    Park, Yunji
    Lee, Seung-Woo
    Kim, Dae Hee
    IMMUNE NETWORK, 2022, 22 (01)
  • [2] Bispecific antibodies in cancer immunotherapy
    Chen, Siqi
    Li, Jing
    Li, Qing
    Wang, Zhong
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (10) : 2491 - 2500
  • [3] Advances in the study of CD47-based bispecific antibody in cancer immunotherapy
    Zhang, Binglei
    Li, Wei
    Fan, Dandan
    Tian, Wenzhi
    Zhou, Jian
    Ji, Zhenyu
    Song, Yongping
    IMMUNOLOGY, 2022, 167 (01) : 15 - 27
  • [4] Bispecific T-cell engagers for cancer immunotherapy
    Huehls, Amelia M.
    Coupet, Tiffany A.
    Sentman, Charles L.
    IMMUNOLOGY AND CELL BIOLOGY, 2015, 93 (03): : 290 - 296
  • [5] Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs
    Stamova, Slava
    Koristka, Stefanie
    Keil, Juliane
    Arndt, Claudia
    Feldmann, Anja
    Michalk, Irene
    Bartsch, Holger
    Bippes, Claudia C.
    Schmitz, Marc
    Cartellieri, Marc
    Bachmann, Michael
    ANTIBODIES, 2012, 1 (02): : 172 - 198
  • [6] Current perspectives of bispecific antibody-based immunotherapy
    Talac, R
    Nelson, H
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2000, 14 (03): : 175 - 181
  • [7] Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
    Ordonez-Reyes, Camila
    Garcia-Robledo, Juan Esteban
    Chamorro, Diego F.
    Mosquera, Andres
    Sussmann, Liliana
    Ruiz-Patino, Alejandro
    Arrieta, Oscar
    Zatarain-Barron, Lucia
    Rojas, Leonardo
    Russo, Alessandro
    de Miguel-Perez, Diego
    Rolfo, Christian
    Cardona, Andres F.
    PHARMACEUTICS, 2022, 14 (06)
  • [8] Current landscape and future directions of bispecific antibodies in cancer immunotherapy
    Wei, Jing
    Yang, Yueyao
    Wang, Gang
    Liu, Ming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] Nanotechnology platforms for cancer immunotherapy
    Yang, Zhaogang
    Ma, Yifan
    Zhao, Hai
    Yuan, Yuan
    Kim, Betty Y. S.
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2020, 12 (02)
  • [10] Bispecific antibodies for cancer therapy: A review
    Krishnamurthy, Anuradha
    Jimeno, Antonio
    PHARMACOLOGY & THERAPEUTICS, 2018, 185 : 122 - 134
12345